NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 7 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
PVP Ventures Reports Q4 FY26 Revenue of ₹41.44 Cr; FY26 Consolidated Revenue Jumps to ₹89.71 Cr
PVP Ventures announced its audited financial results for Q4 and FY26 along with an in-principle approval to amalgamate its wholly-owned subsidiary, PVP Corporate Parks Private Limited. Consolidated revenue from operations for FY26 increased significantly to ₹8,971.09 Lakhs (₹89.71 Cr) from ₹2,720.33 Lakhs in FY25, driven by strong healthcare services contribution of ₹5,678.80 Lakhs. However, consolidated profit before tax for FY26 stood at a loss of ₹842.18 Lakhs, impacted by elevated finance costs of ₹3,350.31 Lakhs. On a standalone basis, FY26 net profit improved to ₹90.99 Lakhs compared to a loss of ₹390.40 Lakhs in FY25.
உச்சம் நம்பிக்கை
என்ன மாறியதுReported audited FY26 financial results showing strong top-line scaling in healthcare, alongside initiating the merger of wholly-owned subsidiary PVP Corporate Parks.
ஏன் இது முக்கியம்Demonstrates operational scaling through acquisitions/diversification into healthcare, but high debt servicing costs continue to weigh heavily on consolidated net profitability.
📅 குறுகிய காலம்Market may look past top-line growth to assess consolidated losses driven by high finance costs.
📈 நீண்ட காலம்Success hinges on cash flow generation from real estate assets and profitability turnaround in the newly expanded healthcare division to service heavy debt loads.
⚠ அபாய எச்சரிக்கைகள்
High finance costs (₹33.50 Cr consolidated in FY26) pressuring bottom line
Healthcare segment reported segment EBIT losses of ₹642.26 Lakhs in FY26
👀 கவனிக்க வேண்டியவை
Track the progress and timeline for regulatory/shareholder approvals regarding the amalgamation of PVP Corporate Parks, and monitor whether healthcare segment margins can offset high finance costs.
Signs LOI for $11-15M procurement of 10 Elekta LINAC systems for healthcare pivot
Evervie Health Limited (formerly PVP Ventures Limited) has signed a Letter of Intent (LOI) with Sweden-based Elekta Solutions AB to procure 10 HARMONY linear accelerator (LINAC) oncology systems. The deal value is estimated between $11 million and $15 million USD (approx. ₹90-125 Cr), which is substantial compared to the company's TTM revenue of ₹118 Cr and market cap of ₹277 Cr. The machines will be operated via its subsidiary, Optimus Oncology Private Limited, with phased deliveries expected through October 2028. The LOI is non-binding and subject to final definitive agreements, financing arrangements, and regulatory approvals.
உச்சம் நம்பிக்கை
என்ன மாறியதுPVP Ventures (renamed Evervie Health) issued a Letter of Intent to procure 10 oncology LINAC systems and launched its new corporate website.
ஏன் இது முக்கியம்Confirms the strategic operational pivot from real estate/media toward specialized healthcare infrastructure, though securing financing remains critical given current debt levels of ₹207 Cr.
Estimated deal value: 11 to 15 million dollars USDNumber of LINAC systems: 10Target completion date: அக்டோபர், 2028Deal value vs Market Cap: ~32% to ~45%
📅 குறுகிய காலம்Market sentiment may react to the concrete expansion into oncology services, but legal binding occurs only after definitive agreement signing.
📈 நீண்ட காலம்If successfully financed and deployed by October 2028, these 10 LINAC systems would provide a recurring revenue stream in oncology radiotherapy, altering the company's business mix away from cyclical real estate.
⚠ அபாய எச்சரிக்கைகள்
LOI is non-binding; definitive agreement is pending
Funding risk given estimated outlay ($11-15M) relative to current debt of ₹207 Cr and net worth of ₹214 Cr
Currency risk as consideration is payable in Swedish krona (SEK)
👀 கவனிக்க வேண்டியவை
Track execution of the definitive Purchase and License Agreement and the closure of debt/equity financing arrangements required to fund this $11-15M procurement.
Evervie Health Pre-pays ₹13.46 Cr NCD Interest Due Across Dec 2026 and Mar 2027
Evervie Health Limited (formerly PVP Ventures Limited) has paid ₹13.46 Cr in advance on 08 October 2026 towards scheduled interest on its Non-Convertible Debentures. The payment covers two upcoming quarters: contractual due dates of 31 December 2026 and 31 March 2027. The interest relates to Series A (₹95 Cr issue size) and Series B (₹55 Cr issue size) debentures, totaling ₹150 Cr in aggregate principal. This prepayment indicates immediate liquidity headroom to service its high-coupon debt obligations.
உச்சம் நம்பிக்கை
என்ன மாறியதுEvervie Health cleared two upcoming quarters of NCD interest payments ahead of schedule on 08 October 2026.
ஏன் இது முக்கியம்Demonstrates near-term liquidity to service ₹150 Cr in high-cost debt, mitigating default risk for the next two quarters.
Total advance interest paid: ₹13.46 கோடிSeries A issue size: ₹95,00,00,000Series B issue size: ₹55,00,00,000Advance interest vs TTM revenue: ~11.4%
📅 குறுகிய காலம்Positive sentiment for credit health, removing near-term debt servicing uncertainty through Q4 FY27.
📈 நீண்ட காலம்Limited; structural debt reduction and cash flow visibility from Project Rainbow and healthcare ventures remain essential for sustainable deleveraging.
⚠ அபாய எச்சரிக்கைகள்
High finance cost load with total debt at ₹207 Cr against net worth of ₹214 Cr
👀 கவனிக்க வேண்டியவை
Track operating cash flows from real estate inventory liquidation and healthcare operations in upcoming quarterly results to verify ongoing debt servicing sustainability.
PVP Ventures CEO & COO Resign w.e.f. September 24, 2026 Prior to Joining
PVP Ventures announced the resignation/cessation of both Dr. Ellen Jane Feehan (Executive Director & CEO) and Dr. Neeraja Nagarajan (Executive Director & COO), effective September 24, 2026. Dr. Feehan cited unavoidable personal and health reasons, terminating her Executive Employment Agreement (signed July 6, 2026) prior to her scheduled joining date of October 1, 2026. Dr. Nagarajan resigned following the non-alignment of Dr. Feehan, citing leadership differentials and personal commitments in the United States. This leaves the top executive management vacant just as the company attempts to pivot into healthcare operations.
உச்சம் நம்பிக்கை
என்ன மாறியதுBoth the incoming CEO and COO have stepped down and terminated their executive engagements effective September 24, 2026.
ஏன் இது முக்கியம்The sudden exit of both the top operating executives disrupts PVP's strategic pivot into healthcare services and leaves leadership continuity uncertain.
Effective cessation date: 24-09-2026Original joining date (CEO): 1st அக்டோபர் 2026EEA execution date: 1st ஜூலை 2026
📅 குறுகிய காலம்Negative sentiment around governance and leadership stability following the abrupt double departure at the executive level.
📈 நீண்ட காலம்Creates execution uncertainty for the company's strategic pivot toward healthcare (Evervie Health / Humain Healthtech) until new leadership is established.
⚠ அபாய எச்சரிக்கைகள்
Key management vacancy at CEO and COO levels simultaneously
Execution delays in the healthcare strategy rollout
👀 கவனிக்க வேண்டியவை
Watch for board announcements regarding interim appointments or new hires for the CEO and COO positions to lead the company's healthcare ventures.
PVP Ventures Executive Director & COO Dr. Neeraja Nagarajan Resigns Effective Sept 24, 2026
PVP Ventures Limited has announced the resignation of Dr. Neeraja Nagarajan from her position as Executive Director & Chief Operating Officer (COO), effective September 24, 2026. The resignation was tendered citing personal reasons. PVP Ventures operates in residential real estate and healthcare services with a market cap of ₹395 Cr and TTM revenue of ₹118 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுDr. Neeraja Nagarajan has stepped down from her operational leadership role as Executive Director and COO effective September 24, 2026.
ஏன் இது முக்கியம்A sudden departure of the COO may create short-term operational execution uncertainty in real estate projects and the scaling healthcare business.
Date of cessation: 24-09-2026சந்தை மதிப்பு: ₹395 கோடிTTM வருவாய்: ₹118 கோடி
📅 குறுகிய காலம்Watch for the announcement of interim leadership or a new COO to handle day-to-day operations.
📈 நீண்ட காலம்Limited, provided the core promoter-led management team remains intact and project execution timelines are maintained.
⚠ அபாய எச்சரிக்கைகள்
Key managerial turnover at the executive level
Operational disruption during ongoing healthcare pivot and real estate launches
👀 கவனிக்க வேண்டியவை
Track announcements regarding the appointment of a successor COO and monitor whether this impacts the operational rollout of ongoing projects like Project Mercury.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Acuité Ratings & Research has assigned an investment-grade rating of 'ACUITE BBB- | Stable' to PVP Ventures Limited's Non-Convertible Debentures (NCDs) aggregating to ₹150.00 Cr. The rated facilities include two long-term tranches of ₹95.00 Cr (ISIN INE362A07054) and ₹55.00 Cr (ISIN INE362A07047). The ₹150.00 Cr rated instruments account for roughly 72.5% of the company's total debt of ₹207 Cr. This rating establishes formal credit benchmarks for the company's long-term borrowing facilities.
உச்சம் நம்பிக்கை
என்ன மாறியதுAcuité Ratings assigned a formal credit rating of 'ACUITE BBB-/Stable' to ₹150 Cr of PVP Ventures' long-term Non-Convertible Debentures across two ISINs.
ஏன் இது முக்கியம்Achieving an investment-grade rating on ₹150 Cr of debt (~72.5% of total debt) validates PVP's creditworthiness and provides institutional visibility for its long-term borrowing structure.
Total NCDs Rated: ₹150.00 கோடிNCD Tranche 1 (INE362A07054): ₹95.00 கோடிNCD Tranche 2 (INE362A07047): ₹55.00 கோடிRated Debt vs Total Debt: ~72.5%Credit Rating Assigned: ACUITE BBB- | Stable
📅 குறுகிய காலம்Neutral to mildly positive for market sentiment as the formal BBB- investment grade credit rating confirms credit standing on listed debentures.
📈 நீண்ட காலம்Facilitates stable borrowing relationships and sets expectations for credit performance as project execution and monetization unfold over FY26-FY30.
⚠ அபாய எச்சரிக்கைகள்
High debt burden with ₹207 Cr total debt against ₹214 Cr net worth (D/E of 0.97)
Significant project execution and cash flow dependency for servicing debt obligations
👀 கவனிக்க வேண்டியவை
Monitor upcoming quarterly interest servicing costs and operational cash flows from residential projects to ensure cash coverage ratios remain adequate for debt obligations.
PVP Ventures has issued a corrigendum to Item No. 10 of its 35th AGM notice scheduled for September 7, 2026. The revised special resolution seeks shareholder approval for the re-appointment of Mr. Prasad V. Potluri as Chairman & Managing Director for a 5-year term ending in 2031. It also seeks approval for managerial remuneration of ₹5.00 crore for FY 2026-27 even in the absence or inadequacy of profits. Additionally, the resolution approves payment of fees to the CMD at 2% p.a. on collateral securities and 1% p.a. on personal guarantees provided for company borrowings.
உச்சம் நம்பிக்கை
என்ன மாறியதுPVP Ventures amended the AGM notice to explicitly include the 5-year re-appointment of CMD Prasad V. Potluri alongside approval of ₹5 Cr remuneration and guarantee fee payouts.
ஏன் இது முக்கியம்The ₹5 Cr remuneration (representing ~4.2% of TTM revenue of ₹118 Cr) plus 1–2% recurring guarantee fees add to annual corporate overheads for a company carrying ₹207 Cr debt and recent net losses.
Proposed CMD Remuneration: Rs.5,00,00,000Remuneration vs TTM Revenue: ~4.2%Collateral Fee Rate: 2% per annumPersonal Guarantee Fee Rate: 1% per annumCMD Re-appointment Term: 5 yearsAGM Date: 07th செப்டம்பர் 2026
📅 குறுகிய காலம்Focus remains on the AGM outcome on September 7, 2026, and whether public/institutional shareholders support the remuneration and guarantee fee structure.
📈 நீண்ட காலம்Continued payouts of ₹5 Cr remuneration and credit enhancement fees will influence cash flow generation as the company executes Project Mercury and services its debt obligations.
⚠ அபாய எச்சரிக்கைகள்
High managerial remuneration relative to net profitability
Related-party transaction fees on collateral and guarantees
Inadequate historical profit coverage
👀 கவனிக்க வேண்டியவை
Track shareholder voting results from the 35th AGM on September 7, 2026, specifically regarding the approval of the special resolution for managerial remuneration and guarantee fees.
PVP Ventures to Rename as Evervie Health; Proposes ₹73 Cr Related Party Transactions
PVP Ventures has issued a notice for its 35th AGM on September 07, 2026, proposing a strategic name change to 'Evervie Health Limited' to reflect its pivot into healthcare services. The company is seeking shareholder approval for material related party transactions (RPTs) totaling ₹73 Cr for FY27, which is significant given its TTM revenue of ₹90 Cr. Additionally, a new 'PVP ESOP Scheme 2026' is proposed, which includes the issuance of new shares that may exceed 1% of the current share capital. The company also plans to appoint M/s. CNGSN & Associates LLP as statutory auditors for a five-year term.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is formalizing its business pivot from construction to healthcare through a corporate rebranding and a new employee stock option framework.
ஏன் இது முக்கியம்The name change signals a definitive long-term strategy shift; however, the high volume of related party transactions (81% of TTM revenue) requires close monitoring for corporate governance.
Total Proposed RPTs: ₹73 கோடிRPTs vs TTM Revenue: 81.1%ESOP Allotment Limit: >1% of share capitalAuditor Term: 5 yearsAGM Date: செப்டம்பர் 07, 2026
📅 குறுகிய காலம்The market may react positively to the clarity provided by the rebranding, though the focus will remain on the upcoming AGM resolutions.
📈 நீண்ட காலம்The structural shift to 'Evervie Health' is critical as the company attempts to move away from its loss-making construction legacy (₹-10 Cr TTM PAT) toward healthcare services.
⚠ அபாய எச்சரிக்கைகள்
High value of Related Party Transactions (₹73 Cr)
Equity dilution from new ESOP issuance
Geographic concentration in Chennai
👀 கவனிக்க வேண்டியவை
Investors should monitor the AGM voting results, specifically the approval of the ₹73 Cr RPTs and the potential equity dilution from the new ESOP scheme.
PVP Ventures Reports ₹15.11 Cr Net Profit in Q1 FY27; CEO Designation Corrected
PVP Ventures reported a significant turnaround in Q1 FY27 with a net profit of ₹15.11 Cr, compared to ₹0.78 Cr in the year-ago period. This performance was heavily bolstered by 'Other Income' of ₹25.43 Cr, which offset an exceptional loss of ₹10.85 Cr. The company also clarified the appointment of Dr. Ellen Jane Feehan as CEO, correcting a previous misclassification. However, a substantial related-party loan of ₹218.43 Cr remains outstanding, with repayment now extended to March 2028.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company returned to significant profitability in Q1 FY27 and corrected its top leadership structure by designating Dr. Ellen Jane Feehan as CEO.
ஏன் இது முக்கியம்The shift to profitability is a positive signal, but the high reliance on non-operational income and the large related-party loan (exceeding the company's net worth) remain critical financial focal points.
Q1 Net Profit: 1,511.16 Lakhsபிற வருமானம்: 2,542.93 LakhsRelated Party Loan: 21,843.49 LakhsLoan vs Net Worth: ~102%Finance Cost: 890.18 Lakhs
📅 குறுகிய காலம்The stock may react positively to the headline profit growth and the formalization of the CEO's role.
📈 நீண்ட காலம்Long-term value depends on the successful execution of the Chennai real estate projects and the actual cash recovery of the large related-party loan.
⚠ அபாய எச்சரிக்கைகள்
High related-party loan exposure (21,843.49 Lakhs)
Reliance on non-operational income for profitability
High finance costs relative to operational revenue
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of operational revenue as 'Other Income' currently drives the bottom line. Watch for the launch of Project Mercury in Q3FY26 and the recovery of the 21,843.49 Lakhs related-party loan by the 2028 deadline.
PVP Ventures increases stake in 7 Med India to 41.23% as part of Rs 127 Cr healthcare pivot
PVP Ventures has completed the second tranche of its acquisition of 7 Med India Private Limited, increasing its stake to 41.23% through the purchase of 4,263 additional shares. The total planned outlay for a 50.62% majority stake is approximately Rs 127 crore, which is highly material as it represents ~141% of PVP's TTM revenue of Rs 90 crore. 7 Med India is a top-five organized player in India's renal care (dialysis) sector, facilitating PVP's strategic pivot into healthcare. The company remains committed to acquiring the remaining stake to reach 50.62% ownership.
உச்சம் நம்பிக்கை
என்ன மாறியதுPVP Ventures has increased its ownership in 7 Med India from an associate level to 41.23%, moving closer to becoming the majority shareholder.
ஏன் இது முக்கியம்This is a significant capital allocation that shifts the company's profile from construction to healthcare, potentially providing more stable cash flows to service its high-cost 18% NCD debt.
Total Deal Outlay: Rs 127 கோடிCurrent Stake: 41.23%Target Stake: 50.62%Deal Value vs TTM Revenue: ~141%Deal Value vs Net Worth: ~59.3%
📅 குறுகிய காலம்The market is likely to view the progress of this large-scale acquisition positively as it clarifies the company's diversification strategy.
📈 நீண்ட காலம்If successfully integrated, the renal care business could fundamentally re-rate PVP from a construction firm to a healthcare-led conglomerate, though high debt servicing remains a long-term hurdle.
⚠ அபாய எச்சரிக்கைகள்
High deal value relative to current revenue
Execution risk in a new business sector (Healthcare)
High debt levels (Rs 207 Cr) with 18% interest obligations
👀 கவனிக்க வேண்டியவை
Monitor the timeline for the final tranche to reach 50.62% and the subsequent impact on consolidated margins, as the company is currently loss-making at the PAT level.
PVP Ventures Defers Rs 150 Cr NCD Principal Repayment to June 2027
PVP Ventures has amended its Debenture Trust Deed to defer the principal repayment of Rs 150 Cr in Non-Convertible Debentures (NCDs) by one year, moving the start date from June 2026 to June 2027. The debt is held by LICHFL funds and carries a high interest rate of 18%. This move provides temporary liquidity relief for the loss-making company (TTM PAT of Rs -10 Cr) as it prepares for the launch of Project Mercury in Q3FY26. However, the high cost of debt and the deferment highlight underlying cash flow pressures.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company successfully negotiated a 12-month extension for the start of principal repayments on its Rs 150 Cr NCDs, originally due in June 2026.
ஏன் இது முக்கியம்This deferment prevents an immediate liquidity crunch but increases the long-term interest burden at a high 18% rate, making the company's turnaround contingent on timely real estate project completions.
Deferred Principal Amount: Rs 150 கோடிDeferred Amount vs TTM Revenue: 166.67%NCD Interest Rate: 18%New Repayment Start Date: ஜூன் 2027Total Debt: Rs 207 கோடி
📅 குறுகிய காலம்Neutral. The deferment removes immediate default risk and provides a 12-month breathing room, which may be viewed as a tactical positive by the market.
📈 நீண்ட காலம்High risk. The company remains structurally challenged by high-cost debt and a loss-making bottom line; long-term stability depends entirely on the Chennai real estate market and project execution.
⚠ அபாய எச்சரிக்கைகள்
High interest cost (18%)
Loss-making operations (TTM PAT Rs -10 Cr)
High debt-to-equity ratio (0.97)
Geographic concentration in Chennai
👀 கவனிக்க வேண்டியவை
Monitor the execution and sales velocity of Project Mercury (launching Q3FY26) and Project Rainbow, as these are the primary cash flow sources required to service the 18% interest debt and meet the revised 2027 repayment deadline.
PVP Ventures Pays ₹3.5 Crore Interest on Non-Convertible Debentures
PVP Ventures Limited has confirmed the timely payment of interest on two series of Non-Convertible Debentures (NCDs) with a combined issue size of ₹150 crore. The company disbursed a total interest amount of approximately ₹3.5 crore on June 24, 2026, meeting its scheduled due date. The payments correspond to ISINs INE362A07054 and INE362A07047, which have issue sizes of ₹95 crore and ₹55 crore respectively. This routine disclosure indicates the company is maintaining its debt servicing obligations as per SEBI regulations.
முக்கிய அம்சங்கள்
Total interest payment of ₹3.5 crore (₹2,21,66,667 and ₹1,28,33,333) completed on June 24, 2026.Serviced debt for two NCD tranches with total issue sizes of ₹95 crore and ₹55 crore.Payment was made on the actual due date with no delays or defaults reported.The record date for identifying beneficial owners was June 23, 2026.Last interest payment for these instruments was previously made on May 20, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view the timely debt servicing as a positive indicator of the company's liquidity and credit discipline. No immediate action is required, but monitoring the company's overall debt-to-equity ratio remains advisable.
PVP Ventures Limited has issued a corrigendum to its Key Information Document regarding the private placement of 15,000 Non-Convertible Debentures (NCDs) totaling ₹150 Crores. The update corrects the coupon payment frequency to quarterly (previously stated as annual) at an 18% interest rate. Additionally, it clarifies the total number of debentures as 15,000 (not 1,500) and provides a detailed quarterly repayment schedule ending April 8, 2029.
முக்கிய அம்சங்கள்
Clarified total issue size of 15,000 Senior Secured NCDs with a face value of ₹1,00,000 each, aggregating to ₹150 Crores.Corrected coupon payment frequency for the 18% interest rate from annual to quarterly compounding.Revised the final redemption date to April 8, 2029, to align with the 48-month tenor from the allotment date.Provided a comprehensive repayment schedule detailing principal and interest outflows starting from March 2026.Confirmed a redemption premium of 1% per annum of the face value payable upon redemption.
👀 கவனிக்க வேண்டியவை
Debt investors should note the quarterly payment cycle and the specific repayment milestones starting in 2026. Equity investors should monitor the company's cash flow to ensure it can service this high-cost (18% coupon) debt obligation.
PVP Ventures Completes Interest Payment of Rs 19.11 Crore on NCDs
PVP Ventures Limited has successfully fulfilled its interest payment obligations for two series of Non-Convertible Debentures (NCDs) with a combined issue size of Rs 150 crore. The company disbursed a total interest amount of approximately Rs 19.11 crore on March 27, 2026, which was ahead of the scheduled due date of March 31, 2026. This timely payment covers two specific ISINs with issue sizes of Rs 95 crore and Rs 55 crore respectively. Such adherence to debt schedules reflects positively on the company's current liquidity management and commitment to its creditors.
முக்கிய அம்சங்கள்
Total interest payment of Rs 19.11 crore made across two NCD tranchesPayment completed on March 27, 2026, four days ahead of the March 31 due dateInterest of Rs 12.10 crore paid on NCD issue size of Rs 95 crore (ISIN: INE362A07054)Interest of Rs 7.01 crore paid on NCD issue size of Rs 55 crore (ISIN: INE362A07047)Last interest payment for these instruments was previously made on February 6, 2026
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the company's ability to service its debt obligations ahead of schedule. No immediate action is required, but it is advisable to monitor the company's long-term debt reduction plans.
PVP Ventures Reports Q3 FY26 Consolidated Net Loss of ₹2.18 Crore Despite Revenue Growth
PVP Ventures Limited reported a significant jump in consolidated total income to ₹10.96 crore for the quarter ended December 31, 2025, up from ₹2.74 crore in the same period last year. However, the company's consolidated net loss widened sharply to ₹2.18 crore compared to a loss of ₹0.08 crore in the previous year's quarter. On a standalone basis, the net loss also increased to ₹4.06 crore from ₹0.74 crore year-on-year. The total comprehensive income for the quarter turned into a loss of ₹2.39 crore against a marginal profit of ₹0.05 crore in Q3 FY25.
முக்கிய அம்சங்கள்
Consolidated total income from operations rose 300% YoY to ₹1,095.58 lacs from ₹273.72 lacs.Consolidated net loss after tax widened significantly to ₹217.99 lacs from ₹8.48 lacs in the year-ago period.Standalone net loss for the quarter increased to ₹405.85 lacs compared to ₹73.52 lacs in Q3 FY25.Consolidated Basic and Diluted EPS for the quarter stood at negative ₹0.09.Equity share capital remained stable at ₹26,040.37 lacs with a face value of ₹10 per share.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company remains loss-making despite a substantial increase in revenue. It is important to analyze the cost structure and exceptional items to understand why the bottom line is not improving with the top line.
PVP Ventures Appoints Dileep Badey as Whole-Time Director for 5 Years
PVP Ventures Limited has announced the appointment of Mr. Dileep Badey as a Whole-Time Director for a five-year term effective March 6, 2026. Mr. Badey, who previously served as the company's Head of Projects, brings over 15 years of experience in real estate development and engineering. Additionally, shareholders approved the appointment of M/s. CNGSN & Associates LLP as the new Statutory Auditor during the Extra-Ordinary General Meeting. These leadership and oversight changes aim to strengthen the company's project execution and governance framework.
முக்கிய அம்சங்கள்
Appointment of Mr. Dileep Badey as Whole-Time Director for a 5-year tenure starting March 6, 2026.Mr. Badey has over 15 years of experience in project management and real estate development.M/s. CNGSN & Associates LLP appointed as Statutory Auditor until the next Annual General Meeting.The appointments were ratified by shareholders at the EGM held on March 6, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's real estate project delivery timelines, as the new director's technical background in construction management is expected to influence execution efficiency.
PVP Ventures Reports Q3 Net Loss of ₹2.18 Crore; Revenue Rises to ₹8.04 Crore
PVP Ventures reported a net loss of ₹2.18 crore for the quarter ended December 31, 2025, showing an improvement from the ₹3.97 crore loss in the preceding quarter. Revenue from operations grew significantly to ₹8.04 crore compared to ₹5.07 crore in the previous quarter. The company continues to be weighed down by high finance costs, which stood at ₹7.23 crore for the quarter. Investors should note the ongoing legal complexities regarding a ₹218.43 crore loan to a related party, though management maintains that the amount is fully recoverable following recent court orders.
முக்கிய அம்சங்கள்
Net loss narrowed to ₹2.18 crore in Q3 FY26 from a loss of ₹3.97 crore in Q2 FY26.Revenue from operations increased by 58.5% quarter-on-quarter to ₹8.04 crore.Finance costs remain high at ₹7.23 crore, representing a significant portion of total expenses.Outstanding loan of ₹218.43 crore to related party NCCPL is subject to legal proceedings with ED and SEBI.Non-Executive Director Mrs. P.J. Bhavani resigned effective February 23, 2026, citing no material reasons.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the progress of the ₹218.43 crore loan recovery and the final resolution of land attachments by SEBI and ED. While operational revenue is improving, the high finance costs and legal overhang remain primary risks.
PVP Ventures to Hold EGM on March 6 for Auditor and Director Appointments
PVP Ventures has scheduled an Extra-Ordinary General Meeting (EGM) for March 6, 2026, to seek shareholder approval for key governance changes. The primary agenda includes the appointment of M/s CNGSN & Associates LLP as Statutory Auditors to fill a casual vacancy following the resignation of the previous firm. Additionally, the company is seeking approval for the appointment of Mr. Dileep Badey as a Whole-time Director for a five-year term. Shareholders as of the February 27, 2026, cut-off date will be eligible to vote on these resolutions.
முக்கிய அம்சங்கள்
EGM scheduled for March 6, 2026, to approve auditor and director appointmentsAppointment of M/s CNGSN & Associates LLP as Statutory Auditors to fill casual vacancyProposed 5-year term for Mr. Dileep Badey as Whole-time Director effective Jan 22, 2026Voting cut-off date set for Feb 27, 2026, with e-voting from March 3-5Auditor change follows the resignation of the previous firm, M/s PSDY & Associates
👀 கவனிக்க வேண்டியவை
Investors should monitor the reasons for the auditor change and review the new director's profile for alignment with company strategy. No immediate action is required beyond participating in the e-voting process.
PVP Ventures Redeems NCD Principal and Interest Worth Rs 8.75 Crore
PVP Ventures Limited has successfully completed a partial redemption of principal and interest for two series of Non-Convertible Debentures (NCDs). On February 6, 2026, the company paid a total of Rs 8.75 crore to debenture holders. This includes a payment of Rs 5.54 crore for an NCD issue of Rs 95 crore and Rs 3.21 crore for an issue of Rs 55 crore. The timely fulfillment of these debt obligations reflects positively on the company's current liquidity position.
முக்கிய அம்சங்கள்
Total payment of Rs 8.75 crore made towards partial redemption and interest on February 6, 2026Payment of Rs 5.54 crore completed for ISIN INE362A07054 (Issue size: Rs 95 Cr)Payment of Rs 3.21 crore completed for ISIN INE362A07047 (Issue size: Rs 55 Cr)Compliance confirmed under Regulation 57 of SEBI (LODR) Regulations, 2015
👀 கவனிக்க வேண்டியவை
Investors should take note of the company's ability to service its debt obligations on time, which is a positive indicator of financial discipline. Continue to monitor the company's overall leverage and cash flow from operations to ensure long-term sustainability.
PVP Ventures Subsidiary Files Compounding Application for Past Non-Compliances
PVP Ventures' material subsidiary, Biohygea Global Private Limited, has filed a compounding application before the NCLT, Chennai. The application seeks to regularize past non-compliances under various provisions of the Companies Act, 2013. While the matter is currently sub-judice, the company has stated that there is no material impact on its operations or financial position. The final penalty amount will be determined once the tribunal passes its order.
முக்கிய அம்சங்கள்
Material subsidiary Biohygea Global Private Limited filed for compounding of offences under the Companies Act, 2013.The application was filed before the Hon’ble National Company Law Tribunal (NCLT), Chennai.The matter pertains to past non-compliances and is currently sub-judice.Management confirms no material impact on current operations or financial stability of the parent or subsidiary.Quantum of penalty, if any, remains unknown until the final disposal of the application.
👀 கவனிக்க வேண்டியவை
Investors should monitor future disclosures regarding the NCLT's final order to assess any potential financial penalty. This move is a standard procedure to clean up historical regulatory lapses and improve corporate governance.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
